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The p53 tumor suppressor continues to be distinguished as the most frequently mutated
gene in human cancer. It is widely believed that the ability of p53 to induce senescence
and programmed cell death underlies the tumor suppressor functions of p53. However,
p53 has a number of other functions that recent data strongly implicate in tumor suppression, particularly with regard to the control of metabolism and ferroptosis (iron- and
lipid-peroxide-mediated cell death) by p53. As reviewed here, the roles of p53 in the control of metabolism and ferroptosis are complex. Wild-type (WT) p53 negatively regulates
lipid synthesis and glycolysis in normal and tumor cells, and positively regulates oxidative
phosphorylation and lipid catabolism. Mutant p53 in tumor cells does the converse, positively regulating lipid synthesis and glycolysis. The role of p53 in ferroptosis is even more
complex: in normal tissues, WT p53 appears to positively regulate ferroptosis, and this
pathway appears to play a role in the ability of basal, unstressed p53 to suppress tumor
initiation and development. In tumors, other regulators of ferroptosis supersede p53’s
role, and WT p53 appears to play a limited role; instead, mutant p53 sensitizes tumor
cells to ferroptosis. By clearly elucidating the roles of WT and mutant p53 in metabolism
and ferroptosis, and establishing these roles in tumor suppression, emerging research
promises to yield new therapeutic avenues for cancer and metabolic diseases.
Keywords: p53, metabolism, ferroptosis, apoptosis, tumor suppressor

INTRODUCTION
The tumor suppressor gene TP53 has been the most heavily studied human gene since its discovery
nearly 40 years ago (1). The main reason behind this status is the critical role p53 plays in preventing
cancer development, and it is widely regarded as the “guardian of the genome.” For some time it has
been generally believed that p53’s role in tumor suppression is by virtue of its ability to induce the
apoptosis, cell cycle arrest, and senescence of pre-cancerous cells (2). However, it is now increasingly
clear that p53 regulates many other pathways in the cell and that these other pathways also play roles
in p53’s ability to function as a tumor suppressor (3). In particular, p53’s role in the regulation of
genes involved in metabolism and ferroptosis has been implicated in its ability to suppress tumor
development. Ferroptosis is a novel cell death pathway first characterized in 2012 and can be best
described as an iron-dependent, caspase-independent form of cell death driven by the formation of
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MUTANT p53 POSITIVELY REGULATES
WARBURG METABOLISM (AEROBIC
GLYCOLYSIS)

lipid peroxidation (4). Specifically, two mouse models containing
engineered mutations in p53 that eliminate the ability of p53 to
induce apoptosis and senescence both retain the ability to suppress
spontaneous tumor development; both of these mutants retain
the ability to transactivate genes in metabolism and ferroptosis
(5, 6). A summary of the data implicating p53 in the regulation
of metabolism and ferroptosis is detailed below.

In contrast to the function of WT p53, mutant p53 in tumor cells
favors aerobic glycolysis, in part by enhancing the trafficking of
the glucose transporter GLUT1 to the plasma membrane, hence
increasing glucose import (14, 15). Following the mutation of p53,
the reduced levels of SCO2 and GLS2 and the increased levels of
GLUT1 and GLUT4 favor aerobic glycolysis over oxidative phosphorylation. In this manner, mutant p53 is believed to contribute
to the propensity of tumor cells to utilize aerobic glycolysis in favor
of oxidative phosphorylation, or so-called Warburg metabolism
(15). One of the hallmarks of cancer is deregulated metabolism,
generally demonstrated by this switch from aerobic glycolysis to
oxidative phosphorylation. Though this results in a lower and less
efficient ATP yield, it is believed that cancer cells benefit by diverting glycolytic intermediates to biosynthetic pathways necessary
for rapid cell division (16). This metabolic switch also leads to
decreased mitochondria-mediated apoptosis and more efficient
signaling through available metabolites in cancer cells (17).

WILD-TYPE (WT) p53 POSITIVELY
REGULATES OXIDATIVE
PHOSPHORYLATION AND SUPPRESSES
GLUCOSE METABOLISM
Wild-type p53 regulates the metabolic versatility of cells by
favoring mitochondrial respiration over glycolysis, in part via
the transactivation of SCO2 (cytochrome c oxidase assembly),
which plays a direct role in oxidative phosphorylation (7). p53 also
directly regulates the transactivation of GLS2 (Glutaminase 2);
this enzyme allows glutamine usage as an energy source for
the mitochondria (8). In addition, WT p53 negatively regulates
glycolysis by transcriptionally repressing the glucose transporters GLUT1 and GLUT4, and by transactivating RRAD and
TIGAR; both are inhibitors of glycolysis (9–11). Finally, p53 also
directly binds and inhibits the enzyme glucose-6-phosphate
dehydrogenase, thus suppressing glucose metabolism (12). It
is clear from these and other studies that in normal, unstressed
organisms, p53 directly regulates the metabolic state in a cell
(Figure 1). Not surprisingly, this gene and many of its regulators are implicated in metabolic diseases, including obesity and
diabetes (13).

A COMMON GENETIC VARIANT IN TP53
INFLUENCES ITS FUNCTION IN
METABOLISM
There is a common coding region polymorphism of p53 at
codon 72, encoding for either proline (P72) or arginine (R72).
This amino acid variation can impact p53 function with regard
to cell fate after stress. In response to DNA damage, the P72

Figure 1 | The role of wild-type (WT) p53 in metabolism. Genes positively regulated by p53 are shown in green, and genes negatively regulated by p53 are shown
in red. p53 inhibits glucose transport, glycolysis, and fatty acid synthesis while it promotes lipid uptake, fatty acid oxidation, oxidative phosphorylation, and
glutaminolysis.
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variant of p53 predominantly triggers cell cycle arrest, while
the R72 variant predominantly induces cell death, or apoptosis
(18, 19). Despite these differences in function, the codon 72
variation has not been consistently associated with cancer
susceptibility (20). By contrast, in human studies this polymorphism is significantly associated with increased body mass
index and risk for diabetes (21, 22). This premise is supported
by studies in mice, where a mouse model for these codon 72
variants shows increased high-fat diet-induced diabetes in mice
with the R72 variant, compared to P72. In these studies, the
p53 target genes TNFα and NPC1L1 were identified as critical
regulators in the increase in diet-induced obesity in R72 mice
(23). Interestingly, the R72 variant has also been shown to
confer increased survival of cells in response to nutrient deprivation (24). These findings have led to the hypothesis that the
R72 variant of p53 arose and was selected for as populations
migrated north, where cold weather would require increased
fat accumulation, but where survival in response to nutrient
deprivation would also be under selection (24).

or energy stress and is known to inhibit fatty acid synthesis by
interacting with acetyl-CoA-carboxylase and SREBP-1 (36, 37).
Zhou and colleagues demonstrated that mutant p53 preferentially
binds to and inhibits AMPK, leading to increased fatty acid synthesis. As a result, mutant p53 proteins lead to increased AMPK
signaling, contributing to invasive cell growth of tumor cells (33).
A lesser explored area is the role of p53 in lipid transport. It has
been shown that p53 transcriptionally regulates apolipoprotein B
(apoB) and apoB editing enzyme complex 1, indicating the role
of p53 in regulating atherogenic lipoproteins (38). Microarray
analysis of human liver-derived cells identified phospholipid
transfer protein, ATP binding cassette A12, and carboxyl ester
lipase as three p53 target genes that all play a role in lipid transport (39, 40). Overall, though it is clear that p53 plays a key role
in mediating lipid synthesis and metabolism, the contribution of
this pathway, and these p53 target genes, to tumor suppression by
p53 remains to be determined (Figure 1).

FERROPTOSIS IS A NOVEL CELL DEATH
PATHWAY DRIVEN BY LIPID
PEROXIDATION

p53 REGULATES LIPID METABOLISM
Though p53 is well known for regulating glycolysis and the citric
acid cycle, p53 also has been shown to play a role in regulating
lipid metabolism (25). It is believed that WT p53 enhances fatty
acid oxidation while inhibiting fatty acid synthesis, thus acting
as a negative regulator of lipid synthesis (25). There are several
p53 target genes with roles in lipid metabolism. Sanchez-Macedo
and colleagues demonstrated that carnitine palmitoyltransferase
1C (CPT1C) is transcriptionally regulated by p53; this enzyme
aids in the transport of activated fatty acids to the mitochondria.
In support of a role for this p53-regulated gene in cancer, this
group showed that Cpt1c-deficient mice display delayed tumor
development and higher survival rates (26). Lipin 1 (LPIN1) is
another p53 target gene; LPIN1 is necessary for proper adipocyte
development and is induced under low nutrient conditions (27).
Finck and colleagues showed that LPIN1 interacts with PGC-1α,
another known p53 target gene with a role in metabolism, and
that this interaction activates the expression of genes involved in
promoting fatty acid oxidation (28).
In addition to directly regulating the transcription of genes
involved in lipid metabolism, p53 can also regulate lipid metabolism in a manner involving direct protein–protein interaction.
For example, glucose-6-phosphate dehydrogenase, which is the
rate-limiting enzyme in the pentose phosphate pathway, binds to
and is directly inhibited by p53, resulting in decreased NADPH
production and consequently decreased fatty acid synthesis (12).
The sterol regulatory element-binding proteins (SREBP) family of
transcription factors modulate the expression of genes involved
in cholesterol, fatty acid, triacylglycerol, and phospholipid synthesis (29–31). WT p53 represses SREBP function (32), while
mutant forms of p53 bind directly to SREBP and enhance their
transcriptional function, leading to increased SREBP activity in
human tumors (33, 34). Consequently, mutant p53 is correlated
with higher expression of sterol biosynthesis genes in human
breast tumors (34, 35). Finally, AMP-activated protein kinase
(AMPK) is an enzyme that is activated under low nutrient levels
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In 2012, Dixon and colleagues discovered a novel form of
regulated cell death called ferroptosis. Ferroptosis is an irondependent, caspase-independent form of cell death resulting
from the accumulation of oxidized lipids (4, 41). This process is
driven by the inactivation of glutathione peroxidase 4 (GPX4),
an enzyme that is responsible for converting lethal lipid hydroperoxides to non-toxic lipid alcohols, which requires glutathione
in order to function (41). It is believed that peroxidation of
polyunsaturated fatty acids (PUFAs) is the driving impetus for
cell death by ferroptosis. PUFAs contain bis-allylic protons that
can easily be abstracted and produce radicals that will react with
oxygen, creating more radicals and resulting in a chain reaction
of lipid reactive oxygen species (42). The exact mechanism of
cell death by ferroptosis remains unknown, but one hypothesis
is that the lipid damage leads to the destruction of the plasma
membrane (43). It has been speculated that ferroptosis could
be a mechanism of tumor suppression that works by eliminating cells that are nutrient deprived or have been exposed to an
environmental stress or infection.

PHARMACOLOGIC REGULATION OF
FERROPTOSIS
Ferroptosis can be induced using inhibitors of system x c− such
as erastin, or analogs such as glutamate and sorafenib, which
inhibit the import of cystine, resulting in depleted glutathione
and subsequent inactivation of GPX4. Alternatively, ferroptosis
can be induced by (1S,3R)-RSL3 (hereafter referred to as RSL3),
which directly binds to and inhibits GPX4 (4, 5, 42). Buthione
sulfoximine, FIN56, FINO2, CCl4, and cisplatin are other agents
that have been demonstrated to induce ferroptosis in cells. Death
by ferroptosis can be prevented by suppressing lipid peroxidation,
which can be accomplished by using lipophilic antioxidants, such
as ferrostatin-1, liproxstatin-1, or vitamin E. Iron chelators such
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led to the upregulation of PTGS2 (41). Notably, PTGS2 was not
upregulated by ferroptosis inducers in p53-null cells, suggesting
that this regulation is p53 dependent (5). Presently, the upregulation of PTGS2 is widely used as a ferroptosis marker (5, 41).
A recent study by the Gu group showed that the p53 target
gene SAT1 regulates ferroptosis (49). The authors identified
SAT1 as a direct target of p53 and showed that silencing of SAT1
reduced cell death induced by reactive oxygen species in cells
with WT p53, but had no effect in p53-null cells. Mechanistically,
this group showed that SAT1 increases the level and activity of
arachidonate 15-lipoxygenase, an iron-binding enzyme that
oxidizes PUFAs and increases lipid peroxidation. Notably, this
study showed that neither p53 nor SAT1 alone appear to be sufficient to induce ferroptosis. Instead, the combined data are more
consistent with the premise that p53, by virtue of regulating genes
that contribute to ferroptosis, regulates the sensitivity of cells to
this pathway, rather than directly induces ferroptosis. Whether
p53 regulates other genes involved in ferroptosis remains to be
determined (Figure 2).

as deferoxamine or cicloprox are another tool used to suppress
ferroptosis by reducing the levels of iron. Depleting PUFAs or
adding monounsaturated fatty acids to cell culture media can also
rescue cells from ferroptosis (42, 44).

FERROPTOSIS IS IMPLICATED IN p53MEDIATED TUMOR SUPPRESSION
In 2012, Gu and colleagues developed a mouse model in which
three normally acetylated lysine residues in the DNA-binding
domain of p53 were mutated to arginine, and therefore could not
be acetylated; this mouse is referred to as the 3KR mouse. Notably,
cells from the 3KR mouse are unable to undergo p53-dependent
apoptosis, cell cycle arrest, or senescence, and indeed the 3KR
mutant of p53 fails to transactivate the majority of p53 target
genes. Interestingly, this mouse model does not spontaneously
develop cancer, implying that p53 could suppress tumor development independent of senescence or apoptosis (45). This group
found that the mutant 3KR protein retains the ability to undergo
ferroptosis and regulate cystine metabolism by regulating the
expression of the cystine importer SLC7A11; this suggested that
ferroptosis might be one pathway that underlies p53-mediated
tumor suppression. When wild type and 3KR MEFs were treated
with the ferroptosis inducer Erastin, almost 50% cell death was
observed whereas p53 null MEFs exhibited 20% cell death; this
indicates that p53 sensitizes cells to ferroptosis, and also that other
key regulators also play a role in ferroptosis (5). Subsequently, Gu
and colleagues identified an additional acetylation site at lysine
98 of p53, and they generated a mouse model in which all four
acetylation sites were mutated to arginine (4KR). Interestingly,
the 4KR mutant was unable to regulate genes involved in ferroptosis like SLC7A11, and unlike the 3KR mutant was unable to
suppress tumor development (46). Though at present correlative,
these data implicate the role of p53 in ferroptosis in its ability to
suppress tumor development.

IN SOME CELLS, p53 NEGATIVELY
REGULATES FERROPTOSIS
A study recently published by Tarangelo and colleagues shows
that p53 negatively regulates ferroptosis in cancer cells (50). This
group found that pre-treating cells with Nutlin-3, a compound
that stabilizes p53 delays the onset of ferroptosis in several cell
types. The delayed onset of ferroptosis was found to depend
on CDKN1A (encoding p21), a critical p53 transcriptional
target. The mechanism through which p21 delays ferroptosis
has yet to be elucidated, but it is believed that the conservation
of intracellular glutathione may be a contributing factor for
reduced ferroptosis sensitivity. The authors conclude that the
p53–p21 axis enables cancer cells to survive under conditions
of metabolic stress, such as cystine deprivation, by suppressing
the onset of ferroptosis (50). A recent study showed that p53
inhibits ferroptosis in colorectal cancer cells by binding to the
enzyme dipeptidyl-peptidase-4 (DPP4), which is a modulator
of ferroptosis and lipid metabolism. Mechanistically, this study
showed that p53 antagonizes ferroptosis by sequestering DPP4 in
a nuclear enzymatic inactive pool. In the absence of p53, DPP4 is
free to interact with and form a complex with NOX1; this leads to
increased lipid peroxidation and ferroptosis. Inhibition of DPP4
suppresses ferroptosis significantly, whereas overexpression of
DPP4 triggers Erastin sensitivity, particularly in p53-depleted
cells (51). The bidirectional control of ferroptosis by p53 through
transcription-dependent and transcription-independent mechanisms may be context or cell-type dependent (Figure 2).

IN NON-TRANSFORMED CELLS, p53
POSITIVELY REGULATES FERROPTOSIS
In addition to SLC7A11, several other direct p53 target genes
have been discovered to play a role in ferroptosis. These include
GLS2, PTGS2, and SAT1. Studies from two separate groups support the role of GLS2 in ferroptosis, which is known to decrease
glutathione and increase cellular ROS levels. Jiang and colleagues
used ferroptosis inhibitors combined with glutaminolysis inhibitors to inhibit Erastin-induced ferroptosis, thereby demonstrating
that ferroptosis requires glutaminolysis and GLS2 (47). Murphy
and colleagues showed that a polymorphic variant of p53 was
able to induce growth arrest and senescence in both human and
murine cells but failed to repress SLC7A11 or transactivate GLS2.
This variant was markedly impaired at inducing ferroptosis and
suppressing tumor development, thus again implicating the role
of p53 in ferroptosis-mediated tumor suppression (48). Another
p53 target gene with a role in ferroptosis is PTGS2, a gene encoding the enzyme cyclooxygenase-2. Stockwell and colleagues first
showed that the induction of ferroptosis using Erastin and RSL3
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THE P47S POLYMORPHISM OF TP53
AFFECTS FERROPTOSIS AND TUMOR
SUPPRESSION
In addition to missense mutations, there are several functionally
significant single-nucleotide polymorphisms (SNPs) in the TP53
gene and other proteins known to regulate this pathway (such as
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Figure 2 | The various roles of p53 in ferroptosis. Inhibition of glutathione peroxidase 4 (GPX4), the key enzyme that catalyzes the conversion of polyunsaturated
fatty acids (PUFAs) containing peroxides to alcohols, is the key driver of ferroptosis. Depending on the context, p53 can suppress ferroptosis (such as in colorectal
cancer cells) or promote ferroptosis. Mutant p53 sensitizes cells to ferroptosis even more than wild-type p53.

MDM2 and MDM4). The Pro47Ser variant (hereafter S47) is the
second most common SNP found in the p53 coding region (after
Pro72Arg) that alters the amino acid sequence of the protein.
To better elucidate the impact of this variant on p53 function
and cancer risk, the Murphy group generated a humanized p53
knock-in mouse model, in which exons 4–9 of murine p53 were
replaced by human p53 exons containing either the wild type or
the S47 variant (52–55). The majority of S47 mice spontaneously
developed tumors of various histologic types, particularly liver
cancer, between 12 and 18 months of age, unlike WT p53 mice
(48). In mouse embryonic fibroblasts and human lymphoblastoid cell lines, the S47 variant showed impaired programmed
cell death in response to cisplatin and other genotoxic stresses.
Mechanistically, the S47 variant is defective for transactivation
of genes involved in metabolism, such as Gls2 (glutaminase 2)
and Sco2 (48). Consistent with the role of Gls2 in ferroptosis,
this group found that S47 cells were markedly resistant to the
ferroptosis-inducing agents Erastin and RSL3 (47, 48). This defect
may contribute to the tumor-prone phenotype observed in S47
mice.

the transcriptional level, and NRF2 has been implicated as a key
player in protecting cancer cells against ferroptosis. For example,
inhibition of NRF2 in hepatocellular cancer cells increases the
anti-cancer activity of Erastin and Sorafenib in vivo (56). Mutant
forms of p53 can inhibit NRF2 function by direct interaction,
and one group found that tumors with mutant p53 contain very
low levels of SLC7A11, and thus show increased sensitivity to
ferroptosis. Notably, overexpression of SLC7A11 in mutant p53
models led to drug resistance, suggesting that levels of SLC7A11
expression must be considered when targeting mutant p53
driven cancers with ferroptosis-inducing compounds (57). In
support of this premise, recent work in colorectal (CRC) cancer,
where mutation or deletion of p53 is a frequent event, showed
that human CRC cell lines harboring mutant p53 were far more
sensitive to Erastin-mediated cell death when compared to CRC
cells with WT p53. To validate these findings, they showed that
knock in of a p53 hotspot mutation in both HCT116 and SW48
cells restored sensitivity to Erastin (51). These data highlight a
novel mechanism by which cancers driven by mutant p53 can be
exploited using targeted therapy.

MUTANT p53 SENSITIZES TUMOR CELLS
TO FERROPTOSIS

CONCLUSION
The role of p53 in metabolism is quite clear and possibly even
intuitively obvious: WT p53 limits glucose metabolism and lipid
synthesis, while mutant p53 appears to do the opposite. The contribution of its metabolic role to tumor suppression by p53, and
to the ability of mutant p53 to drive tumor progression, remains
to be unequivocally proven. The role of p53 in the regulation
of ferroptosis, and the contribution of this function, to tumor

Wild-type p53 negatively regulates the expression of the cystine
importer SLC7A11, which inhibits sensitivity to ferroptosis (5).
Although this regulation occurs in normal cells, in tumor cells,
other mediators of SLC7A11 appear to predominate in the regulation of this gene. For example, the master antioxidant transcription factor NRF2 can also regulate the expression of SLC7A11 at
Frontiers in Endocrinology | www.frontiersin.org
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suppression is even less clear. While compelling data from mouse
models supports the premise that p53 regulates the sensitivity
of cells to ferroptosis, this may be restricted to the ability of
basal p53 to suppress spontaneous tumor development, and in
oncogene-stressed mouse models, it is clear that senescence and
apoptosis play the predominant role. Similarly, p53 may regulate
ferroptosis sensitivity in a cell type-specific manner. More studies in animal models, with attention to ferroptosis in different
tissues, need to be done to more fully understand the role of p53
in ferroptosis and ferroptosis in tumor suppression. Additionally,
a clearer idea of what p53-target genes play a role in sensitivity
to ferroptosis needs to be attained. Resolution of these questions
should provide for much needed novel avenues to combat tumors
with mutant p53.
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